Physician profile
Jane Presti
NPI 1871802140
$1,566.98
in general payments reported to CMS, 2019-2025
20 companies · $157 in 2025
The $157 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $283 · 2020: $257 · 2021: $196 · 2022: $179 · 2023: $301 · 2024: $194 · 2025: $157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $652.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $652.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $287.39 | 2022-2025 | Azstarys |
| Glaxosmithkline, LLC. | $232.79 | 2019-2025 | Bexsero, Pediarix, Rotarix |
| Takeda Pharmaceuticals U.S.A., INC. | $200.46 | 2019-2022 | |
| Pfizer INC. | $163.83 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $152.81 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Cranial Technologies, INC | $121.34 | 2019-2020 | |
| Sanofi Pasteur INC. | $74.08 | 2019-2024 | |
| Alk-Abello, INC | $53.44 | 2023-2024 | Odactra, Ragwitek, Grastek |
| Arbor Pharmaceuticals, INC. | $44.30 | 2019 | |
| Adlon Therapeutics L.P. | $38.67 | 2020 | |
| Genentech USA, INC. | $37.95 | 2019-2020 | |
| Organon LLC | $30.85 | 2025 | |
| Tris Pharma INC | $29.04 | 2022-2023 | Dyanavel Xr |
| Ultragenyx Pharmaceutical INC. | $15.00 | 2021 | |
| Seqirus USA INC | $14.90 | 2025 | Flucelvax |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $14.68 | 2019 | |
| Aytu Biopharma, INC. | $14.63 | 2021 | |
| Kaleo, INC. | $14.38 | 2023 | Auvi-Q |
| Dermira, INC. | $13.85 | 2020 | |
| Supernus Pharmaceuticals, INC. | $12.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Presti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.